Tag Archives: EXAS

EXACT Sciences Co. (EXAS) Expected to Announce Quarterly Sales of $103.93 Million

Wall Street brokerages forecast that EXACT Sciences Co. (NASDAQ:EXAS) will report $103.93 million in sales for the current fiscal quarter, according to Zacks. Five analysts have made estimates for EXACT Sciences’ earnings. The highest sales estimate is $105.51 million and the lowest is $101.66 million. EXACT Sciences reported sales of $57.65 million in the same quarter last year, which indicates a positive year over year growth rate of 80.3%. The business is scheduled to report its next quarterly earnings report on Tuesday, July 24th.

On average, analysts expect that EXACT Sciences will report full-year sales of $430.94 million for the current year, with estimates ranging from $429.20 million to $432.20 million. For the next financial year, analysts anticipate that the firm will report sales of $640.83 million per share, with estimates ranging from $624.15 million to $658.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover EXACT Sciences.

Get EXACT Sciences alerts:

EXACT Sciences (NASDAQ:EXAS) last issued its earnings results on Thursday, April 26th. The medical research company reported ($0.33) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.05. EXACT Sciences had a negative return on equity of 20.92% and a negative net margin of 38.61%. The business had revenue of $90.30 million during the quarter, compared to analyst estimates of $86.31 million. During the same quarter in the previous year, the firm earned ($0.32) EPS. EXACT Sciences’s revenue was up 86.7% on a year-over-year basis.

A number of brokerages have weighed in on EXAS. Canaccord Genuity boosted their target price on EXACT Sciences from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, April 27th. BTIG Research reissued a “buy” rating and issued a $60.00 target price on shares of EXACT Sciences in a research report on Sunday, April 29th. BidaskClub raised EXACT Sciences from a “hold” rating to a “buy” rating in a research report on Friday, April 20th. Zacks Investment Research lowered EXACT Sciences from a “hold” rating to a “sell” rating in a research report on Friday, April 27th. Finally, ValuEngine upgraded EXACT Sciences from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $53.84.

EXACT Sciences traded up $0.70, reaching $52.39, during mid-day trading on Monday, Marketbeat Ratings reports. The company’s stock had a trading volume of 1,205,700 shares, compared to its average volume of 2,828,373. EXACT Sciences has a 12-month low of $29.45 and a 12-month high of $63.60. The company has a debt-to-equity ratio of 0.71, a quick ratio of 14.86 and a current ratio of 15.30. The firm has a market cap of $6.28 billion, a price-to-earnings ratio of -52.92 and a beta of 0.86.

In related news, Director Michael S. Wyzga sold 7,402 shares of the business’s stock in a transaction that occurred on Thursday, May 10th. The stock was sold at an average price of $51.53, for a total transaction of $381,425.06. Following the completion of the transaction, the director now directly owns 10,974 shares in the company, valued at approximately $565,490.22. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Thomas D. Carey sold 8,448 shares of the business’s stock in a transaction that occurred on Tuesday, April 10th. The shares were sold at an average price of $39.73, for a total value of $335,639.04. Following the transaction, the director now owns 52,610 shares of the company’s stock, valued at $2,090,195.30. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 135,748 shares of company stock valued at $6,082,759. Corporate insiders own 4.00% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. Elk Creek Partners LLC grew its stake in shares of EXACT Sciences by 66.5% during the 1st quarter. Elk Creek Partners LLC now owns 962,731 shares of the medical research company’s stock valued at $38,827,000 after acquiring an additional 384,481 shares during the period. OppenheimerFunds Inc. grew its stake in shares of EXACT Sciences by 99.6% during the 1st quarter. OppenheimerFunds Inc. now owns 5,831,347 shares of the medical research company’s stock valued at $235,179,000 after acquiring an additional 2,910,506 shares during the period. GSA Capital Partners LLP bought a new position in shares of EXACT Sciences during the 1st quarter valued at approximately $331,000. Sei Investments Co. grew its stake in shares of EXACT Sciences by 114.8% during the 1st quarter. Sei Investments Co. now owns 97,625 shares of the medical research company’s stock valued at $3,936,000 after acquiring an additional 52,180 shares during the period. Finally, Quantbot Technologies LP bought a new position in shares of EXACT Sciences during the 1st quarter valued at approximately $135,000. Institutional investors own 81.88% of the company’s stock.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Get a free copy of the Zacks research report on EXACT Sciences (EXAS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for EXACT Sciences (NASDAQ:EXAS)